Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | MAT2A | P31153 | 3/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525524 | 0.84 | KDM4E (0.55) | HTR3AHRH4PDE10AKDM1AALDH1A1 | |
| SCHEMBL9430149 | 0.83 | MAT2A (0.51) | HTR3AHRH4PDE10ACSF1RMAT2A | |
| SCHEMBL939079 | 0.83 | HTR3A (0.42) | HTR3AHRH4PDE10AKDM1A | |
| SCHEMBL23601070 | 0.82 | CSF1R (0.68) | CSF1RKDM1A | |
| SCHEMBL8381530 | 0.81 | ACP1 (0.42) | HTR3AHRH4PDE10ACSF1RFABP3 | |
| SCHEMBL938619 | 0.80 | EGFR (0.55) | CSF1RKDM1ACYP2C9ALDH1A1 | |
| SCHEMBL1084347 | 0.79 | HTR3A (0.65) | HTR3AHRH4PDE10ACSF1RMAT2A | |
| SCHEMBL1084629 | 0.78 | EGFR (0.59) | CYP2C9ALDH1A1 | |
| SCHEMBL1084101 | 0.77 | HTR3A (0.62) | HTR3AHRH4PDE10ACSF1RMAT2A | |
| SCHEMBL3114872 | 0.77 | EGFR (0.72) | CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092065-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| WO-2023133217-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-2854804-B1 | PYRROLIDINO HETEROCYCLES | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-9540384-B2 | Pyrrolidino heterocycles | HOFFMANN-LA ROCHE, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2854804-A1 | PYRROLIDINO HETEROCYCLES | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20150087644-A1 | PYRROLIDINO HETEROCYCLES | HOFFMANN-LA ROCHE INC. (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2013178569-A1 | PYRROLIDINO HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092065-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SNRPA, SNRPB2, HNRNPAB | HTR3A 3524/4885HRH4 3883/4885PDE10A 3949/4885 |
| US-20150087644-A1 | PYRROLIDINO HETEROCYCLES | PDE3A, PDE3B, PDE2A | HTR3A 1060/4885HRH4 1215/4885PDE10A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.